Hikma soars on growth upgrade

Pharmaceuticals group Hikma yesterday raised its growth forecasts for the year, sending its shares up 5.63 per cent. The FTSE 250-listed firm said it expects revenues to rise 17 per cent in 2013, up from previous guidance of around 13 per cent. Chief executive Samih Darwazah said Hikma is performing well across all of its businesses.

Related articles